Phaseline

Companies › Livzon Pharmaceutical Group

Livzon Pharmaceutical Group: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 1 Phase 2, 1 Phase 3; Cardiovascular, Gastroenterology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
JP-1366
Proton pump inhibitor
–Phase 3Reflux Esophagitis (RE)–
H001 Capsule–Phase 2Circulatory Disease–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06850480JP-1366Phase 3Reflux Esophagitis (RE)GastroenterologyApr 2025
NCT06963320H001 CapsulePhase 2Circulatory DiseaseCardiovascularJun 2025

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Matrix Biomed Shin Poong Pharmaceutical Noorik Biopharmaceuticals Getz Pharma Beijing Continent Pharmaceutical

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.